8 November 2024
EMADOC-1700519818-1721693
Committee for Veterinary Medicinal Products (CVMP)

Summary of opinion[1] (post-authorisation)

Simparica Trio

International non-proprietary name (INN): sarolaner / moxidectin / pyrantel embonate

On 7 November 2024, the Committee for Veterinary Medicinal Products (CVMP) adopted an opinion[2], recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Simparica Trio. The marketing authorisation holder for this veterinary medicinal product is Zoetis Belgium.

Simparica Trio is currently authorised as chewable tablets for dogs. The variation concerns the addition of a new therapeutic indication for the treatment of the lungworm *Angiostrongylus vasorum* and the amendment of the contact details for the reporting of suspected adverse events, provided in the package leaflet.

Detailed conditions for the use of this product are described in the updated summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged.